Johan Noble
Overview
Explore the profile of Johan Noble including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Noble J, Anglicheau D, Blancho G, Bertrand D, Couzi L, Durrbach A, et al.
Nephrol Ther
. 2025 Mar;
21(1):37-47.
PMID: 40066607
The standard immunosuppressive treatment after organ transplantation typically includes a calcineurin inhibitor (tacrolimus or cyclosporine A), an antimetabolite (mycophenolic acid) or an mTOR inhibitor, and corticosteroids. However, these treatments are...
2.
Perrier Q, Noble J, Lablanche S
Transplant Rev (Orlando)
. 2025 Mar;
39(2):100913.
PMID: 40048867
Beta-cell replacement therapies, including islet and pancreas transplantation, offer promising results in term of glycemic control for patients with type 1 diabetes experiencing high glycemic variability and severe hypoglycemia. However,...
3.
Garrouste C, Poirier P, Uro-Coste C, Iriart X, Kamar N, Bonhomme J, et al.
Transpl Int
. 2024 Dec;
37:13518.
PMID: 39726674
Trial Registration Number: ClinicalTrials.gov ID: NCT05417815.
4.
Perrier Q, Noble J, Bonadona A, Augier C, Jouve T, Boignard A, et al.
Vaccine
. 2024 Dec;
45():126617.
PMID: 39700906
Objectives: SARS-CoV-2 mRNA vaccine reactogenicity has raised concerns regarding the risk of rejection in solid organ transplant recipients. We explored whether SOT recipients diagnosed with acute rejection had previously received...
5.
Naciri Bennani H, Bobo Barry K, Noble J, Malvezzi P, Jouve T, Rostaing L
Front Immunol
. 2024 Dec;
15:1504495.
PMID: 39687613
Background: ABO-incompatible kidney transplantation (ABOi-KTx) represents a possible solution to address the shortage of kidney donors. However, these transplants present immunological challenges, particularly when isoagglutinin titers are elevated pretransplant. Methods:...
6.
Noble J, Cabezas L, Truffot A, Dumolard L, Jouve T, Malvezzi P, et al.
Transpl Int
. 2024 Nov;
37:13876.
PMID: 39559251
[This corrects the article DOI: 10.3389/ti.2024.13029.].
7.
Gineste A, Malvezzi P, Jouve T, Millet C, Rostaing L, Noble J
Clin Kidney J
. 2024 Oct;
17(8):sfae182.
PMID: 39421236
Background: The rising prevalence of end-stage renal failure in the elderly has led to an increased number of kidney transplantations in older individuals. While age does not solely determine transplant...
8.
Arrive C, Bazzoli C, Jouve T, Noble J, Rostaing L, Stanke-Labesque F, et al.
BioDrugs
. 2024 Aug;
38(5):703-716.
PMID: 39147956
Background: Tocilizumab prevents the clinical worsening of chronic active antibody-mediated rejection (CAAMR) in kidney transplant recipients. Following a global shortage of the intravenous pharmaceutical form in 2022, patients were switched...
9.
Noble J, Cabezas L, Truffot A, Dumolard L, Jouve T, Malvezzi P, et al.
Transpl Int
. 2024 Jul;
37:13029.
PMID: 39081904
Despite the growing use of desensitization strategies, hyperimmune patients remain at high risk of antibody-mediated rejection suggesting that, even when donor-specific antibodies (DSA) are effectively depleted, anti-donor specific B cells...
10.
Cabezas L, Truffot A, Germi R, Bugnazet M, Malvezzi P, Gnesotto M, et al.
Kidney Int Rep
. 2024 Jun;
9(6):1718-1729.
PMID: 38899180
Introduction: Belatacept is a relevant alternative to calcineurin inhibitors (CNIs) after kidney transplantation (KT). Circulating Torque Teno virus (TTV) DNA load is correlated to infections and rejection risks post-KT in...